15/10/2018 - 13:17

PharmAust progresses to next step in dog drug tests

15/10/2018 - 13:17

Bookmark

Upgrade your subscription to use this feature.

ASX listed biotech PharmAust now has sufficient data from testing of different tablet prototypes of its flagship Monepantel anti-cancer drug to take the best performing and most economical tablet for GMP manufacturing. The selected tablets will be used in formal dose escalation studies in healthy Beagle dogs to determine the maximum dose that can be given and with what safety margin.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options